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Background: A glycoproteomic study has previously shown cadherin-5 (CDH5) to be a serological marker of metastatic
breast cancer when both protein levels and glycosylation status were assessed. In this study we aimed to further validate the utility
of CDH5 as a biomarker for breast cancer progression.
Methods: A nested case–control study of serum samples from breast cancer patients, of which n¼ 52 had developed a distant
metastatic recurrence within 5 years post-diagnosis and n¼ 60 had remained recurrence-free. ELISAs were used to quantify
patient serum CDH5 levels and assess glycosylation by Helix pomatia agglutinin (HPA) binding. Clinicopathological, treatment
and lifestyle factors associated with metastasis and elevated biomarker levels were identified.
Results: Elevated CDH5 levels (P¼ 0.028) and ratios of CDH5:HPA binding (P¼ 0.007) distinguished patients with metastatic
disease from those that remained metastasis-free. Multivariate analysis showed that the association between CDH5:HPA ratio and
the formation of distant metastases was driven by patients with oestrogen receptor (ERþ ) positive cancer with vascular invasion
(VIþ ).
Conclusions: CDH5 levels and the CDH5 glycosylation represent biomarker tests that distinguish patients with metastatic breast
cancer from those that remain metastasis-free. The test reached optimal sensitivity and specificity in ER-positive cancers with
vascular invasion.
Serum tumour markers are economic, non-invasive tests that can
be used to aid diagnosis, to monitor disease progression and
patient response to treatment. In order for oncologists to tailor
individual treatment strategies, breast cancer patients with the
highest risk of developing metastatic disease need to be classified to
identify those most likely to benefit from adjuvant therapy, whilst
minimising the number of women receiving unnecessary therapies.
Two of the most widely utilised breast cancer biomarkers are
cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen
(CEA), measured after primary breast cancer treatment for the
detection of recurrent disease or metastasis (Sturgeon et al, 2008,
2009). However, the most appropriate use of tumour markers for
monitoring breast cancer progression remains the subject of
considerable debate in the scientific community (Mirabelli and
Incoronato, 2013). Recently, new imaging techniques have been
allied with serum tumour marker measurements to identify
cancerous lesions non-detectable by conventional imaging mod-
alities, for example, positron emission tomography imaging has
*Correspondence: Dr MV Dwek; E-mail: m.v.dwek@westminster.ac.uk
Revised 14 July 2015; accepted 13 January 2016
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
FULL PAPER
Keywords: breast cancer; metastasis; biomarker; glycosylation; cadherin-5; ER positive; vascular invasion
British Journal of Cancer (2016), 1–8 | doi: 10.1038/bjc.2016.66
www.bjcancer.com |DOI:10.1038/bjc.2016.66 1Advance Online Publication: 24 March 2016
been shown to detect breast cancer recurrence and metastasis in
patients with rising levels of tumour markers such as CA15.3
(Champion et al, 2011; Katayama et al, 2012). This provides a
renewed impetus in the search for serum markers for breast cancer
which may allay the criticism current markers have attracted,
whilst increasing the diagnostic ability of imaging techniques.
Many serological cancer biomarkers are glycoproteins. Glycosyla-
tion is one of the most frequent post translational modifications to
occur on proteins (Khoury et al, 2011), but in the majority of
diagnostic tests protein levels are monitored whilst the glycan moiety,
and therefore biological information possibly pertaining to pathology,
is ignored. As aberrant glycosylation is known to accompany
malignant transformation, this offers potential for refinement of
cancer serum biomarker tests (Kuzmanov et al, 2013). In an attempt
to address the under-exploitation of glycosylation for breast cancer
biomarker discovery, we previously employed a glycoproteomic
approach and reported many serum proteins with altered glycosyla-
tion in metastatic breast cancer. Using this approach, cadherin-5
(CDH5) emerged as a novel biomarker for metastatic breast cancer
(Fry et al, 2013), when assessed by ELISAs that incorporate
measurements of glycosylation status, evaluated by binding of the
lectin Helix pomatia agglutinin (HPA) known to detect poor
prognosis metastatic cancer (Schumacher and Adam, 1997;
Mitchell and Schumacher, 1999; Dwek et al, 2001).
In this study we aimed to further determine the utility of CDH5
as a biomarker for breast cancer progression by identifying
clinicopathological, treatment and lifestyle factors associated with
metastasis and elevated biomarker levels. Serum samples from
breast cancer patients were analysed to obtain measurements of
CDH5 and to determine the glycosylation status as monitored by
HPA binding. The CDH5:HPA test emerged as a novel means for
detection of metastatic breast cancer in patients with ER-positive
tumours that have infiltrated the vasculature.
MATERIALS AND METHODS
Patient samples. Serum samples were routinely collected as part
of the DietCompLyf study (Swann et al, 2013) approved by
the UCL/UCLH Committees on the Ethics of Human Research
(ref. 96/3433 and 98/0090). All patients consented to participation
in the study. n¼ 2808 breast cancer patients were recruited onto
the study (new protocol) 9–15 months post breast cancer
diagnosis, whereupon the first of five annual venipunctures was
performed and blood was collected into 6ml vacutainers (BD
Bioscience, Plymouth, UK), left to stand for 1 h to clot, centrifuged
at 1200 g for 15min and the resulting supernatant aliquoted into
0.5ml fractions and frozen at  20 1C or  70 1C. Patients
(n¼ 207) developed distant metastases by October 2012, of which
n¼ 120 had available serum samples from year 1 and at least one
other year of the DietCompLyf study. Serum samples were
analysed from 2 patient groups; those with no sign of distant
metastatic recurrence (NSR) 48 months (±3 months) post
recruitment (60 months ±3 months post-diagnosis), and those
with distant metastatic recurrence (REC) within the same time
period. NSR and REC patient groups were selected according to
their age at diagnosis, tumour size, grade, lymph node, oestrogen
receptor, progesterone receptor and human epidermal growth
factor receptor 2 statuses, Table 1.
Sample size calculation. The CDH5 levels recorded previously (Fry
et al, 2013) for patients with either NSR (m1) or REC (m2) were used
to estimate the sample size required in each group using the following
equation: n¼ 2 (sd)2 (zaþ zb)2/(m1m2)2 using multipliers
based on significance level (za) and power (zb; Suresh and
Chandrashekara, 2012). This identified a sample size of 92 samples
per group to achieve 95% significance and 90% power. After analysis
of n¼ 60 NSR and n¼ 52 REC samples, statistical significance was
reached for the CDH5 ELISAs and to preserve the DietCompLyf
sample bank no further serum testing was performed.
CDH5 ELISA. Ninety-six-well plates (Immuno Maxisorp,
Thermo Scientific, Loughborough, UK) were coated with 50 ml
mouse monoclonal anti-human CDH5 (MM0012-8A03, Insight
Biotechnology, Middlesex, UK) diluted to 0.2 mgml 1 in carbo-
nate/bicarbonate buffer, pH 9.6, by overnight incubation at 4 1C.
All subsequent steps were undertaken at room temperature on an
orbital shaker. Wells were washed five times with 200 ml
phosphate-buffered saline/0.1% (v/v) Tween 20 (PBS/T), blocked
by addition of 200 ml Carbofree Solution (Vector Labs, Peterbor-
ough, UK) for 30min and then washed a further five times with
200 ml PBS/T. Patient sera were diluted 1 in 50 and 1 in 250 in PBS.
25 ml of each dilution was added to wells in duplicate followed by
addition of 50 ml Carbofree solution to each well. Plates were
incubated for 2 h, washed five times with 200 ml PBS/T, and then
50 ml of biotinylated goat polyclonal anti-human CDH5 (N-14,
Insight Biotechnology) prepared at 0.5mgml 1 in Carbofree
solution was added for 1 h. Wells were washed four times with
200 ml PBS/T and 50 ml of streptavidin conjugated to poly-horse
radish peroxidase (Thermo Scientific) diluted 1 : 4000 in Carbofree
Solution was added for 1 h. Wells were washed three times with
200 ml PBS/T followed by a further three times with deionised
water before addition of 100 ml 3,30,5,50-tetramethylbenzidine
(TMB) microwell peroxidase substrate (Insight Biotechnology).
The reaction was monitored using a Dynatech MRX plate reader
(Dynatech Medical Products, Alexandria, VA, USA) and quenched
by addition of 100 ml 1 M phosphoric acid when the absorbance
measured at 630 nm reached B0.6 absorbance units. Following
quenching the absorbance was read at 450 nm in a Wallac 1420
Victor 2 plate reader (Perkin Elmer, Beaconsfield, UK).
Refined CDH5 ELISA to measure CDH5 glycosylation status.
Ninety-six-well plates were coated, incubated and then washed as
described in the previous section. Seventy-five microlitre of cold
20mM periodic acid was added to each well for 30min at 4 1C.
Following five washes with 200ml PBS/T plates were blocked and
washed as before. Patient serum was diluted 1 in 25 and 1 in 125 in
PBS. Twenty-five microlitre of each dilution was added to wells in
duplicate, before addition of 50ml Carbofree solution to each well.
Plates were incubated for 2h, washed five times with 200ml PBS/T,
and then 50ml of biotinylated HPA (Sigma Aldrich, Dorset, UK) at
10mgml 1 in Carbofree solution was added for 1h. Wells were
washed as before and 50ml of streptavidin conjugated to poly-horse
radish peroxidase diluted 1 : 1000 in Carbofree solution was added for
1 h. Wells were washed three times with 200ml PBS/T followed by a
further three times with deionised water before addition of 100ml
TMB microwell peroxidase substrate. The reaction was monitored
and the absorbance read as described above.
Quantification of CA15.3 and CEA. CA15.3 and CEA serum
measurements were made by The Doctors Laboratory (TDL,
London, UK), an independent clinical pathology accredited
laboratory. CA15.3 and CEA were quantified by the Roche
Modular method.
VEGF ELISA. Serum VEGF levels were measured using a human
‘VEGF DuoSet ELISA development system kit’ (R&D Systems,
Oxon, UK) according to the manufacturer’s instructions with the
following alterations: 100 ml streptavidin-HRP from the kit was
replaced with streptavidin conjugated to poly-horseradish perox-
idase (Thermo Scientific) diluted 1 : 4000 in reagent diluent; patient
sera were diluted 1 : 10 in reagent diluent and assayed in duplicate;
the uppermost point on the standard curve was 500 pgml 1
(seven point standard curve). These alterations were made to
enhance the sensitivity of the assay to minimise the volume of
patient serum required.
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Sample analysis. For the CDH5 ELISAs described above, two-fold
serial dilutions of pooled reference serum with known CDH5
concentration were used to produce standard curves. Standard
curves were measured in duplicate on each 96-well plate, with the
limit of detection defined as the mean average blank reading (wells
containing all reagents but no serum) plus two s.d.’s. Levels of
CDH5 and HPA binding for the patient samples were determined
by interpolation against the standard curves (after subtraction of
blank readings from the standard curves and from the patient
serum absorbance values). Three quality control samples were
assayed on each plate to enable inter-assay comparison. The
highest absorbance reading falling within the linear detection range
on the standard curves was used to infer the relative protein levels,
taking into account any dilution factor.
The CDH5, HPA, CDH5:HPA ratio, CA15.3, CEA and VEGF
values were analysed as continuous variables using the Mann–
Whitney test to assess biomarker discrimination between NSR and
REC samples. Univariate analysis using the Kruskal–Wallis or
Table 1. Descriptive covariates, showing clinicopathological, treatment and lifestyle features of patients from which the samples
were taken as well as the results that were obtained for biomarker measurement
NSR (n¼60) REC (n¼52) Total subjects (n¼112)
Mean (s.d.) Range Mean (s.d.) Range Mean (s.d.) Range
Age at diagnosis * 52.19 (9.29) 33.45–71.76 53.21 (11.51) 31.80–74.50 52.66 (10.29) 31.80–74.50
Tumour size (mm) * 24.14 (15.53) 2–70 28.54 (20.51) 5–110 26.15 (18.02) 2–110
Height (m) 1.63 (0.06) 1.50–1.79 1.63 (0.07) 1.47–1.80 1.63 (0.06) 1.47–1.80
Weight at diagnosis (kg) 72.41 (13.60) 51.5–114.0 69.64 (14.20) 47.7–127.0 71.12 (13.60) 47.7–127.0
BMI at diagnosis 27.31 (4.81) 17.61–39.02 26.14 (5.02) 17.95–43.84 26.76 (4.92) 17.61–43.84
CDH5 (ngml 1) 9.51 (9.84) 0.12–43.03 13.77 (13.93) 0.03–79.10 11.49 (12.05) 0.03–79.10
HPA (AUml 1) 151.98 (143.56) 3.22–611.27 144.64 (137.34) 11.26–839.78 148.58 (140.11) 3.22–839.78
CDH5/HPA ratio (ngAU1) 0.085 (0.067) 0.003–0.296 0.114 (0.083) 0.001–0.586 0.098 (0.076) 0.001–0.586
n % n % n %
Grade 1 3 5.0 2 3.8 5 4.5
Grade 2 * 22 36.7 20 38.5 42 37.5
Grade 3 35 58.3 30 57.7 65 58.0
Lymph node -ve 26 43.3 22 42.3 48 42.9
Lymph node 1–3 þ ve * 21 35.0 13 25.0 34 30.4
Lymph node 43 þ ve 13 21.7 17 32.7 30 26.8
ER positive 44 73.3 32 61.5 76 67.9
ER negative * 16 26.7 20 38.5 36 32.1
PR positive 20 33.3 18 34.6 38 33.9
PR negative * 22 36.7 16 30.8 38 33.9
HER2 positive 13 21.7 15 28.8 28 25.0
HER2 negative * 37 61.7 26 50.0 63 56.3
Vascular Invasion 25 41.7 29 55.8 54 48.2
No vascular invasion 33 55.0 23 44.2 56 50.0
Local recurrence 1 1.7 5 9.6 6 5.4
No local recurrence 59 98.3 47 90.4 106 94.6
Pre-menopausal 14 23.3 15 28.8 29 25.9
Peri-menopausal 15 25.0 11 21.2 26 23.2
Post-menopausal 31 51.7 25 48.1 56 50.0
Blood group A 26 43.3 20 38.5 46 41.1
Blood group B 8 13.3 1 1.9 9 8.0
Blood group AB 6 10.0 4 7.7 10 8.9
Blood group O 20 33.3 27 51.9 47 42.0
Neoadjuvant chemotherapy 3 5.0 9 17.3 12 10.7
No neoadjuvant chemotherapy 57 95.0 43 82.7 100 89.3
Adjuvant Chemotherapy 44 73.3 34 65.4 78 69.6
No adjuvant chemotherapy 16 26.7 18 34.6 34 30.4
Tamoxifen 29 48.3 21 40.4 50 44.6
Arimidex/anastrozole 11 18.3 8 15.4 19 17.0
Herceptin 7 11.7 5 9.6 12 10.7
Other 6 10.1 4 7.6 10 9.0
None 7 11.7 14 26.9 21 18.8
Current smoker 3 5.0 2 3.8 5 4.5
Ex-smoker 20 33.3 14 26.9 34 30.4
Non-smoker 36 60.0 31 59.6 67 59.8
Current drinker 50 83.3 37 71.2 87 77.7
Former drinker 2 3.3 3 5.8 5 4.5
Non-drinker 7 11.7 7 13.5 14 12.5
Abbreviations: BMI¼body mass index; CDH5¼ cadherin-5; ER¼oestrogen receptor; HER2¼ receptor tyrosine-protein kinase erbB-2; HPA¼helix pomatia agglutinin; NSR¼ no sign of
recurrence; PR¼progesterone receptor; REC¼ recurrent breast cancer. NSR and REC patients were matched according to asterisked categories. Where percentages do not total 100, the
absent data was not collected and/or is unknown.
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Mann–Whitney test was employed to assess associations between
patient CDH5:HPA ratios and clinicopathological, treatment and
lifestyle factors. The same tests were used to establish whether an
association between CDH5:HPA ratios and any of these factors was
evident when comparing NSR patients with REC patients.
Using multiple logistic regression models, the clinicopathologi-
cal variables shown in table one were built into models in a
stepwise manner to determine their capability in prediction of
distant recurrence. The sensitivity, specificity and the negative and
positive predictive values (NPV/PPV) were determined.
RESULTS
CDH5–HPA ELISAs. Levels of CDH5 were determined in breast
cancer serum samples by interpolation from standard curves
showing intra- and inter-assay coefficients of variation of 6.8% and
15.3%, respectively. The highly reproducible nature of the CDH5
assay is further evidenced by them all falling within the 95%
confidence interval of the combined mean of all curves, R2¼ 0.993
(Figure 1A). To allow inter-assay comparisons, three quality
control serum samples were included on each 96-well plate,
specifically selected to represent a range of CDH5 concentrations
(Figure 1B). The linear working range of the assay was 21–
330 pgml 1. As expected, the quality control sample with the
lowest CDH5 concentration showed the greatest degree of
variability, accordingly, the patient sample dilution of the greatest
optical density falling within the linear range of the standard curve
was used to determine the CDH5 levels (Figure 1B). In all, 52 out
of the 112 patient samples analysed had detectable CDH5 levels in
both serum dilutions assayed. When the data were normalised to
equivalent concentrations of serum, the coefficient of variation
between sample dilutions was 13.5% and general agreement
between CDH5 concentrations measured at each dilution (1 in
50 and 1 in 250) was good (Spearman rank correlation
coefficient¼ 0.85, Po0.0001; Supplementary Figure 1A).
The ELISA was refined by pre-treating the capture antibody
with periodic acid to oxidise vicinal diols of the glycans to aldehyde
groups, rendering the capture antibody non-reactive with HPA.
The refined ELISA therefore was used to measure the glycosylation
status of the CDH5 protein. The pooled reference serum was used
to generate standard curves: mean R2¼ 0.992 (Figure 1C). Intra-
and inter-assay coefficients of variation were 5.9% and 12.2%,
respectively. Again, three quality control samples were incorpo-
rated on each plate to assess assay reproducibility. One NSR and
one REC patient had non-detectable HPA binding levels at both of
the serum dilutions assayed, and 66 out of 110 patient samples
analysed had HPA levels that were detectable at both serum
dilutions. Agreement between sample dilutions was not quite as
good as observed in the CDH5 ELISA, with an average coefficient
of variation of 24.9% after normalising the data to equivalent
volumes of serum, Spearman correlation¼ 0.78, Po0.0001
(Supplementary Figure 1B).
Biomarker levels discriminate between NSR and REC. Table 1
presents data showing that patients with recurrent breast cancer
had significantly higher levels of serum CDH5 compared with
patients that remained recurrence-free for 5 years (P¼ 0.028,
Figure 2A) and whilst HPA binding was comparable between the 2
sample groups (Figure 2B) the CDH5:HPA ratio was also
significantly elevated (P¼ 0.007) in patients with REC compared
with patients with NSR (Figure 2C).
CA15.3 and CEA are the most widely investigated serum
biomarkers for breast cancer (Duffy, 2006), both of which show
elevated levels in a proportion of patients with metastatic disease
(Cheung et al, 2000). Of the initial cohort of 112 breast cancer patient
serum samples analysed, 70 (n¼ 41 NSR, n¼ 29 REC) had sufficient
volume remaining for measurements of CA15.3 and CEA. Figure 2D
shows that patients with recurrent breast cancer had significantly
higher levels of serum CA15.3 compared with patients that remained
recurrence-free for 5 years (P¼ 0.0164). CEA measurements did not
distinguish NSR from REC samples (Figure 2E).
VEGF has been shown to be associated with tumour angiogenesis
(Rykala et al, 2011). To assess whether the CDH5 levels detected
in the patient serum samples were associated with an increased level
of circulating VEGF, and potentially, therefore, tumour angiogenesis,
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Figure 1. CDH5 ELISA standard curves and quality control samples. (A) CDH5 standard curves (broken lines) with mean values indicated. (B)
CDH5 QC samples, with inter-assay variability on right hand axis. (C) Refined ELISA (for HPA binding measurement) standard curves (broken lines)
with mean value indicated. (D) Refined ELISA QC samples, with inter-assay variability on right hand axis.
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of 3.9–500pgml 1 VEGF in serum. Approximately half of the serum
samples from the breast cancer patients had detectable levels of serum
VEGF, however, no significant difference (P¼ 0.75) in the VEGF levels
were observed between the two patients groups: NSR and REC
(Figure 2F). Similarly, there was no statistically significant association
between the levels of serum VEGF and either the CDH5, HPA or
CDH5:HPA ratio values, (Spearman’s rank correlation, P40.05).
Statistical analysis of clinicopathological, treatment and lifestyle
factors. When all 112 patients were analysed, no statistically
significant differences in the distribution of CDH5:HPA ratios
were found for any clinicopathological, treatment or lifestyle
factors (Table 1). The CDH5:HPA ratios were significantly
increased (Mann–Whitney or the Kruskal–Wallis tests) in patients
who had developed recurrences (n¼ 51) compared with those with
no sign of recurrence (n¼ 59) when tumour size, vascular
invasion, lymph node involvement, menopausal and ER, PR and
HER2 status, treatment (Tamoxifen, neoadjuvant chemotherapy)
and lifestyle factors (alcohol consumption, BMI and smoking
status) were considered, Figure 3.
The influence of the following clinicopathological parameters on
the chance of developing distant metastasis was investigated: tumour
size (continuous variable), tumour grade, vascular invasion, lymph
node status, ER, PR, HER2 status and CDH5:HPA ratio. The
CDH5:HPA ratio data showed significant positive skew, and thus
was considered as a categorical variable (according to tertiles:
low¼ 0.007–0.062 ngAU 1 (n¼ 36), mid¼ 0.062–0.117 ngAU 1
(n¼ 37), high¼ 0.117–0.586ngAU 1 (n¼ 37)) in the logistic
regression model which predicted breast cancer metastasis in a
statistically significant manner (P¼ 0.036). The accuracy of this
model for classification of breast cancer metastasis was 72.6%;
specificity and sensitivity was 74.3% and 70.4%, respectively
(Supplementary Table 1). On examination, ER status (P¼ 0.024),
CDH5:HPA ratio (P¼ 0.030) and vascular invasion (P¼ 0.038)
were all statistically significant suggesting that the CDH5:HPA ratio
is of greatest utility as a predictor of breast cancer metastasis in ER
positive tumours that have vascular invasion.
Sensitivity and specificity. A receiver operating characteristic
(ROC) curve was plotted and the optimal sensitivity, specificity,
PPV and NPV of CDH5:HPA ratio for the detection of metastatic
breast cancer was calculated with data from 110 samples
(Figure 4A). Using the Youden index to apply equal emphasis to
minimise false positive and negative readings, the CDH5:HPA
ratio distinguished NSR from REC serum samples with 84.3%
specificity and 47.5% sensitivity, with corresponding PPV and
NPV values of 58.1% and 77.8%, respectively. When the results
from patients with ER-positive tumours with vascular invasion
were considered, the CDH5:HPA ratio was able to further
discriminate between NSR and REC breast cancer patients. In this
analysis the sensitivity and specificity reached 82.4% and 73.7%,
respectively, the PPV was 73.7% and the NPV was 82.4%
(Figure 4A). The sensitivity of the CDH5:HPA ratio assay was
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Figure 2. Box plots showing biomarker levels in patients with either NSR or REC. (A) CDH; (B) HPA binding to (antibody) captured CDH; (C) Ratio
of CDH5:HPA; (D) CA15.3; (E) CEA; (F) VEGF. The whiskers represent the data within 1.5 IQR of the upper and lower quartiles. Outliers are
indicated by dots. Statistical significance indicated.
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maximal at 94.1% (NPV¼ 92.3%) with a concomitant reduction in
specificity to 63.2% (PPV¼ 69.6%).
ROC analysis of the sub-cohort of 70 patients from which serum
CA15.3 was quantified revealed that CA15.3 is a more specific
marker of metastatic breast cancer than CDH:HPA (70.7% and
46.3%, respectively), whilst CDH:HPA is more sensitive (89.7% vs
62.1%, Figure 4B). Combining CA15.3 and CDH:HPA ratio values
did not significantly increase the area under the ROC curve (AUC)
relative to AUCs obtained for CA15.3 or CDH:HPA individually
(data not shown).
CDH5:HPA ratio tertiles. When taken as a continuous variable
the CDH5:HPA ratio did not correlate with time to, or the site of,
metastasis (data not shown). However, when considered
as a categorical variable 78% of breast cancer patients with a
CDH5:HPA ratio in the low category (n¼ 36) were metastasis-free
after 5 years (w2(1, N¼ 36)¼ 5.56, P¼ 0.0184). This figure fell to
43% and 40% for patients with CDH5:HPA ratios in the mid and
high categories, respectively. When considering only those patients
with ER-positive tumours with vascular invasion, 92% of those in
the low CDH5:HPA ratio category remained metastasis-free after
5 years (w2(1, N¼ 12)¼ 4.17, P¼ 0.0412; Figure 5).
DISCUSSION
A previous glycoproteomic investigation identified CDH5 as a novel
biomarker of metastatic breast cancer. An ELISA-based methodol-
ogy was developed to enable the CDH5 protein levels to be
measured in the serum of breast cancer patients alongside
assessment of CDH5 glycosylation status using HPA as the glycan
recognition molecule (Fry et al, 2013). The assays were employed in
this study of a new set of serum samples from the DietCompLyf
cohort (Swann et al, 2013). Comparable results to those obtained
previously were observed, further strengthening the evidence for
CDH5 as a biomarker of breast cancer metastasis and demonstrating
the importance of assessing both the protein level and glycosylation
status. Both the CDH5 protein level and the CDH5:HPA ratio were
significantly increased in the sera of patients with metastatic breast
cancer compared to patients that remained disease free for 5 years
post breast cancer diagnosis. The data from ELISAs suggests that
CDH5 and CDH5:HPA ratio values may offer a lead time in the
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Figure 3. Box plots showing clinicopathological, treatment and
lifestyle factors (listed from most to least significant) that distinguish
NSR and REC patients when their ratio of CDH5:HPA binding is
assessed. The whiskers represent data within 1.5 IQR of the upper
and lower quartiles. Outliers are indicated by dots. Significance



















































































Figure 4. ROC curves plotted to calculate sensitivity, specificity, PPV and NPV. (A) CDH5:HPA ratio for all patients (solid line) and for vascular
invasion positive, ER-positive patients (broken line). (B) Comparison of CA15.3, CEA and CDH:HPA.
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(from diagnosis) in this cohort of patients was 32.0 months (±3
months) post primary breast cancer diagnosis.
Serial measurements of CA15.3 have been shown to detect
recurrent/metastatic disease with a lead time of 2–9 months (Duffy,
2006). Consistent with this, serum CA15.3 measurements were shown
to discriminate patients with metastatic breast cancer from patients
that remained disease free for 5 years. As the most commonly
employed marker for breast cancer, CA15.3 is widely considered as
the gold standard against which other markers must be compared.
Thus, it is encouraging that measurement of serum CDH5 protein
levels compared favourably to those of CA15.3 in discriminating
metastatic breast cancer sera. When comparing CA15.3 to the
CDH:HPA ratio values, the most specific test, least likely to lead to
false positive classifications, is CA15.3. Conversely, CDH:HPA ratio
values produce a more sensitive test for metastatic breast cancer.
CDH5 is a cell membrane glycoprotein found at adherens
junctions where it acts as an adhesion receptor between non-
proliferative endothelial cells (Giannotta et al, 2013). The first
report of aberrant levels of CDH5 in cancer was in uveal melanoma
in 2001 (reported in Breier et al, 2014), since then CDH5 has also
been implicated in aggressive breast cancer (Parker et al, 2004;
Labelle et al, 2008). A murine model of mammary carcinogenesis
revealed that cells that had undergone epithelial to mesenchymal
transition (EMT), a phenotypic alteration associated with meta-
static dissemination (Kalluri and Weinberg, 2009), had increased
tumour cell proliferation and increased cancer cell adhesion to
endothelial cells associated with increased cell surface CDH5.
In addition, CDH5 promoted breast cancer progression via the
transforming growth factor b (TGF-b) signalling pathway (Labelle
et al, 2008) the same pathway that promotes cell proliferation and
EMT in tumours with an invasive cellular phenotype (Yilmaz and
Christofori, 2009). The interaction between CDH5 and TGF-b
receptors has been demonstrated to enhance TGF-b signalling in
endothelial cells (Rudini et al, 2008). CDH5 and VEGF are
recognised mediators of tumour angiogenesis, a process required
for invasion and metastasis of solid tumours (Weidner et al, 1991),
and VEGF inhibitors have been approved for the treatment of
advanced cancer (Longatto Filho et al, 2010). In this study, serum
VEGF levels did not distinguish patients with metastatic disease
from patients with no sign of metastasis, consistent with a recent
report in which lymphovascular invasion rather than angiogenesis
was associated with poorer recurrence-free and cancer-specific
survival (Mohammed et al, 2013), suggestive that tumour growth is
dependent on angiogenesis, whilst lymphovascular invasion may
be essential for metastasis.
Univariate analysis revealed that patients with recurrent breast
cancer and significantly elevated CDH5:HPA ratios typically had
vascular invasion, X4 positive lymph nodes and a tumour
420mm in diameter (Weigelt et al, 2005). Post-menopausal ER-
and PR-positive breast cancer patients with metastatic disease
showed significantly raised CDH5:HPA ratios compared with
those who remained metastasis-free. As would be expected, the
majority of the breast cancer patients studied here were treated
with the hormone therapy Tamoxifen, and this was associated with
an increased CDH5:HPA ratio. As the majority of newly diagnosed
breast cancers are ER positive (Yasui and Potter, 1999; Anderson
et al, 2002; Piccart-Gebhart, 2011) it is therefore encouraging that
the CDH5:HPA ratio was able to discriminate ER-positive breast
cancer patients with different clinical outcomes. Similarly the
CDH5:HPA ratio was elevated in the serum of HER2-positive
breast cancer patients who developed recurrent disease.
Alcohol consumption and obesity are modifiable factors that have
previously been linked to increased breast cancer recurrence rates.
Alcohol drinkers and patients with a high BMI (25–29.9 kgm 2) at
diagnosis, as well as non-smokers, showed significantly raised
CDH5:HPA ratios associated with the formation of distant metastases
but the significance of these findings is unclear.
Multivariate analysis showed that the CDH5:HPA ratio best
predicts breast cancer metastasis in ER-positive tumours where the
tumour has invaded the vasculature (Figure 4A). Stratifying patients
according to ER status and vascular invasion had negligible effect on
the sensitivity or NPV of the CDH5:HPA assay, but dramatically
increased the specificity and PPV. High specificity and NPV are
desirable attributes for biomarkers of metastatic cancer minimising
false positives and are important for optimal patient management in
the clinic. Of the sample set analysed here, 74% of patients with an
ER-positive primary tumour with vascular invasion were ectly
identified as developing distant metastases, and 82% of patients
stratified in the same way were correctly identified as remaining
metastasis-free for 5 years. Taking the lower tertile of CDH5:HPA
ratios (0.007–0.062ngAU 1) revealed that 11 of the 12 ER-positive
vascular invasion positive patients remained free of distant metastases
for 5 years. Clearly, the utility of the biomarker tests described here
will require further investigation using analytical methods such as
Kaplan–Meier and Cox’s regression to determine the relationship
between biomarker levels and time to breast cancer recurrence.
In conclusion, the assays described here to measure pgml 1
levels of serum CDH5 and probe CDH5 glycosylation are sensitive,
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Figure 5. Distribution of all patients (A) and vascular invasion positive,
ER-positive patients (B) with metastatic breast cancer according to
tertiles of CDH5:HPA ratio. w2 P-values indicated.
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ratio values showed these biomarkers to be significantly elevated in
patients with metastatic breast cancer, a finding which was
paralleled by measurements of CA15.3, which is a more specific
but less sensitive marker than CDH:HPA ratios. Univariate
analysis revealed that CDH5:HPA ratios correlated with several
prognostic indicators for breast cancer metastasis. Multivariate
analysis showed that patients with ER-positive cancer with vascular
invasion were driving the association between the CDH5:HPA
ratio and the formation of distant metastases. The CDH5:HPA
ratio detected patients with recurrent breast cancer with ER-
positive primary tumours containing vascular invasion with 82%
sensitivity and 74% specificity. In the lower tertile of CDH5:HPA
ratios, 92% of patients with ER-positive primary tumours
containing vascular invasion had no sign of distant metastasis,
indicating the sub-group of breast cancer patients for whom
measurement of this biomarker is the most beneficial.
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